Anticancer effect of long-circulating nanometer liposome packaging cisplatin in vitro and in vivo

GE Yongqian,ZHANG Xiaomeng,LING Yunhua,YANG Huanjun,RUI Mengjie,CHEN Jian,XU Yuhong
DOI: https://doi.org/10.3969/j.issn.1007-4406.2008.04.003
2008-01-01
Abstract:AIM To explore the anticancer effect of the long-circulating liposome packaging eisplatin (LDDP) in vitro and in vivo.METHODS In vitro,the cytotoxicity of LDDP,cisplatin (CDDP) and the lipid of LDDP,was stud- ied in A549 lung cancer cells with MTT assay.In vivo,the anticancer effect of LDDP and CDDP was determined in the C57BL/6N mice bearing Lewis lung carcinoma.The LDDP or CDDP with the dosage of 6 mg·kg~(-1) was injected into the mice's tail vein after the tumor size reached 8 mm in diameter (about 2 wk later).Tumor size was measured three times a week,until the death of mice or 60 d.The time of the tumor volume increasing quintuples (t_(5v)) and the survival peri- od of the mice were evaluated.The tumor volume growth delay (TGD) time was calculated.RESULTS The lipid used in the preparation of LDDP was proved no cytotoxicity to A549 cell line.The inhibitive rate of LDDP to A540 cell line was greater than that of CDDP.The IC_(50) of CDDP was almost two times of LDDP (3.25 mg·L~(-1) vs 1.72 mg·L~(-1)).In C57BL/6N mice beating Lewis lung carcinoma,the injection of LDDP resulted in longer tumor growth delay time than CDDP [ (12.79±3.8) d vs (3.84±1.97) d,P<0.01].LDDP administration also prolonged the median survival of mice (41.5 d vs 25.0 d,P<0.01).CONCLUSION The long-circulating liposome packaging cisplatin produces greater anticancer effect than CDDP both in vitro and in vivo experiments.
What problem does this paper attempt to address?